Therapy Type: Small Molecule
Target Type: APP and Amyloid-Related (timeline), Metals
Condition(s): Alzheimer's Disease, Huntington's Disease
U.S. FDA Status: Alzheimer's Disease (Phase 2), Huntington's Disease (Phase 2)
Company: Prana Biotechnology Limited
PBT2 is a second-generation metal-protein attenuating compound (MPAC). It does not act as a metal chelator but rather as an ionophore that facilitates translocation of copper and zinc. It is thought that by facilitating the translocation of copper and zinc into the cell, PBT2 reduces extracellular levels of these metals and thereby reduces metal-mediated Aβ aggregation (Lannfelt et al., 2008; Crouch et al., 2011).
The association of metal ions (copper, zinc, and iron) with Aβ promotes its aggregation (Bush et al., 1994).
No Available References
No Available Further Reading